ImmunoGen (IMGN) Reveals Mirvetuximab Phase II Design at Investor Day; RBC Affirms at 'Outperform'
Tweet Send to a Friend
RBC Capital affirms ImmunoGen (Nasdaq: IMGN) at Outperform with a price target of $20 after the company unveiled its mirvetuximab ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
